Equities

Kane Biotech Inc

KNBIF:QBB

Kane Biotech Inc

Actions
  • Price (USD)0.0931
  • Today's Change0.00 / 0.00%
  • Shares traded100.00
  • 1 Year change+45.45%
  • Beta--
Data delayed at least 15 minutes, as of Jun 20 2024 14:30 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Kane Biotech Inc. is a Canada-based biotechnology company. The Company is engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. It has a portfolio of biotechnologies and products, which includes StrixNB, DispersinB, Aledex, bluestem, bluestem, silkstem, goldstem, coactiv+, coactiv+, DermaKB and DermaKB Biofilm. Its Wound Care & Surgical division is focused on the product development of DispersinB for applications in chronic wound care. Its bluestem product line includes water additives, chews, spray and dental wipes. Its other products in development stage include Coactiv+, antimicrobial wound rinse for use in acute and chronic wounds; Coactiv+, antimicrobial surgical hydrogel for use in surgical and acute wounds, and DispersinB Gel for prosthetic joint infection. It also provides Scalp Detoxifier, Shampoo and Shampoo Bars. Its primary markets for its technologies are animal health and human health.

  • Revenue in CAD (TTM)165.60k
  • Net income in CAD-4.94m
  • Incorporated2003
  • Employees--
  • Location
    Kane Biotech Inc290-100 Innovation DriveWINNIPEG R3T 6G2CanadaCAN
  • Phone+1 (204) 453-1301
  • Fax+1 (204) 474-7552
  • Websitehttps://kanebiotech.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.